Pyrotinib Plus Vinorelbine in HER2+ Metastatic Breast Cancer Patients

Completed

• Conditions: Breast Cancer

• Registration Number: NCT04517305
• Lead Sponsor: Fudan University

Brief Summary

To evaluate the patterns and treatment outcomes of pyrotinib plus vinorelbine in the real world.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2018-05-15
• Study First Submitted: 2020-08-16
• Study First Submitted QC: 2020-08-16
• Study First Posted: 2020-08-18
• Primary Completion: 2021-05-15
• Study Completion: 2021-05-15
• Status Verified: 2021-06
• Last Update Submitted: 2021-06-17
• Last Update Posted: 2021-06-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 97

Inclusion Criteria

• woman, age > 18 years old
• diagnosed with HER2 +Metastatic Breast Cancer
• pyrotinib plus vinorelbine for at least one cycle, starting from 2018.05-2020.05
• available medical history

Read More

Exclusion Criteria

• medical history was incomplete

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
PFS	6 weeks	Progression free survival
Adverse events	6 weeks	Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)

Trial Locations

Locations (1)

Fudan University Shanghai Cancer Center; 🇨🇳 Shanghai, Shanghai, China